Cartesian Therapeutics granted new employee an option to purchase company stock

From GlobeNewswire: 2025-03-06 07:05:00

Cartesian Therapeutics, Inc. announced the granting of an inducement award to a new employee, which includes an option to purchase 2,650 shares of the Company’s common stock at $17.50 per share. The option will vest over time, with full vesting by March 3, 2029, and has a ten-year term. Cartesian Therapeutics is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, with its lead asset, Descartes-08, in Phase 2b clinical development for generalized myasthenia gravis and systemic lupus erythematosus. For more information, visit www.cartesiantherapeutics.com.



Read more at GlobeNewswire: Cartesian Therapeutics Announces New Employment Inducement